VA-REGULA-FORENSICS
8.6.2021 14:02:08 CEST | Business Wire | Press release
Permission.io, the digital advertising platform that lets online marketers reward users for interacting with ads, announces the integration with the Regula Document Reader SDK to cover the full know-your-customer (KYC) process. The partnership mitigates the risk of fraud and delivers a verified audience to advertisers.
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. With 28 years of experience, Regula is a trusted name to experts in both the private and public sectors worldwide. The company has the industry’s largest database of document templates and uses artificial intelligence to automatically determine document type and reveal the visual signs of fraud. Proprietary Face Matching and Liveness Detection technologies make Regula a one-stop solution for identity verification.
Permission.io is a digital advertising platform that enables consumers to earn rewards for interacting with advertisements. The company uses blockchain technology to allow advertisers to reward consumers with ASK, the platform’s native digital currency, for signing up, providing profile and preference data, engaging with video ads, referring friends, and other activities.
“Digital Advertising is ripe for a change,” said Charles Silver, CEO of Permission.io . “Big tech exploits user data, and click fraud is estimated to grow into an $87 billion business in 2021. The major platforms grade their own homework, so to speak, and advertisers are getting the short end of the stick. Too often, the ads they pay to deliver are not even being seen. Permission is bringing the change this industry needs by respecting user data and by delivering to advertisers superior targeting and better ROI on their considerable spend.”
“Financial technology needs the most secure protection from fraud, and we’re happy to share our expertise in document forensics with emerging industry leaders to ensure clear and reliable fraud detection while onboarding and asset management,” said Arif Mamedov, President of Regula Forensics Inc . “Our web and mobile products have been designed to meet the requirements of fintech and to be seamlessly integrable into any scenario and interface.”
Regula Document Reader SDK parses documents and extracts personal data, eliminating manual data input and minimizing mistakes. When it comes to data validation, Regula’s technology cross-checks the data obtained from MRZ, VIZ, and barcodes. The process of user identification is completed with face matching in seconds, while the personal data is secured by the internal Permission network. “We are very excited to add Regula's invaluable expertise to our promise to prevent identity fraud and deliver a delightful user experience,” Silver said.
About Regula Forensics:
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. Regula’s software product suite includes ID verification, facematching and liveness technologies for mobile applications and web-based solutions, to build a seamless on-premises digital identity and biometric verification workflow.
135 international borders are equipped with Regula hardware and software products. Regula is an official partner of the UN, Interpol, OSCE, IATA and ICAO. For more information, visit https://mobile.regulaforensics.com .
About Permission.io:
Permission.io is the leading platform for permission advertising for eCommerce. The company has created the ASK digital currency to enable individuals to securely grant permission and monetize their data on Permission.io and 3rd-party e-commerce platforms. Advertisers reward consumers with ASK for interacting with brands and content, building trust, and increasing ROI. To learn more, visit https://permission.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005012/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
